/ Active, not recruiting临床1/2期 A Phase 1/2 Randomized Study to Evaluate the Safety and Tolerability of Intracarotid Artery Administration of NCS-01 in Patients With Acute Ischemic Stroke
This is an initial Phase1/2 dose-finding, randomized, multi-center study to evaluate the safety and tolerability of NCS-01 in patients with acute ischemic stroke. All patients will be randomized within 48 hours of stroke onset. This study will be conducted in 2 stages.
100 项与 NC Medial Research Inc 相关的临床结果
0 项与 NC Medial Research Inc 相关的专利（医药）
100 项与 NC Medial Research Inc 相关的药物交易
100 项与 NC Medial Research Inc 相关的转化医学
